Numerous biological events need to be orchestrated at an epigenetic level upon defining cellular fate. Among the key epigenetic regulators are protein methyltransferases (PMTs), which methylate specific Arg/Lys residues with S-adenosyl-L- methionine (SAM) as a cofactor. Whereas many recombinant PMTs are active in vitro, their cellular activities can largely depend on the presence of distinct PMT isoforms or complexes. Such context- dependent complexity makes it challenging to solely rely on conventional methods to elucidate the targets of PMTs. The flexible substrate-recognizing patterns of PMTs, together with their highly- conserved SAM-binding motifs, also made it challenging to develop PMT inhibitors with potency and selectivity. A long-term goal of the project is to elucidate and manipulate methyltransferase- involved epigenetic for disease diagnosis and treatments. The objective of this application is to use SAM mimics as probes to profile cell-type-specific substrates of PMTs and to perturb PMTs in a specific manner. Here an integrative Bioorthogonal Profiling of Protein Methylation (BPPM) will be implemented to dissect the substrates of designated PMTs in relevant biological contexts. A subtype of methylation events associated with specific biological processes will be further validated with well-established methods. Their functional roles will be examined in the context of cancer malignancy or stem cell reprogramming. In parallel, stable SAM analogues will be pursued as target-specific inhibitors against PMTs. The completion of this proposal will unambiguously reveal the substrates of multiple PMTs and characterize high-quality PMT inhibitors in relevant cellular contexts. The impact of these substrate-profiling and inhibitor-identifying strategies further lie n their general applicability to other methyltransferases.
This proposal is expected to uncover the targets of biologically relevant methyltransferases and expand the current collection of methyltransferase inhibitors. The methylation events associated with disease malignancy will be validated and the corresponding inhibitors will be characterized. This work is expected to elicit disease-associated biology and lead to potential therapeutic reagents.
|Luo, Minkui (2018) Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chem Rev 118:6656-6705|
|Quintero, Cynthia M; Laursen, Kristian B; Mongan, Nigel P et al. (2018) CARM1 (PRMT4) Acts as a Transcriptional Coactivator during Retinoic Acid-Induced Embryonic Stem Cell Differentiation. J Mol Biol 430:4168-4182|
|Shu, Xiao; Dai, Qing; Wu, Tong et al. (2017) N6-Allyladenosine: A New Small Molecule for RNA Labeling Identified by Mutation Assay. J Am Chem Soc 139:17213-17216|
|Luo, Minkui (2017) Inhibition of the Kinase Cascade Can Be Quantitative. Biochemistry 56:4443-4444|
|LaFave, Lindsay M; Béguelin, Wendy; Koche, Richard et al. (2016) Reply to ""Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"". Nat Med 22:578-9|
|Wu, Hong; Zheng, Weihong; Eram, Mohammad S et al. (2016) Structural basis of arginine asymmetrical dimethylation by PRMT6. Biochem J 473:3049-63|
|Linscott, Joshua A; Kapilashrami, Kanishk; Wang, Zhen et al. (2016) Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8. Proc Natl Acad Sci U S A 113:E8369-E8378|
|Tang, Haiping; Chen, Yuling; Liu, Xiaohui et al. (2016) Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma. Oncotarget 7:38822-38834|
|Aldawsari, Fahad S; Aguayo-Ortiz, Rodrigo; Kapilashrami, Kanishk et al. (2016) Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents. J Enzyme Inhib Med Chem 31:695-703|
|Warrier, Thulasi; Kapilashrami, Kanishk; Argyrou, Argyrides et al. (2016) N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:E4523-30|
Showing the most recent 10 out of 34 publications